Literature DB >> 10948033

Drug treatment of multiple sclerosis.

C H Polman1, B M Uitdehaag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10948033      PMCID： PMC1118391          DOI： 10.1136/bmj.321.7259.490

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  25 in total

1.  Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study.

Authors:  G Comi; F Barkhof; L Durelli; G Edan; O Fernandez; M Filippi; H P Hartung; O R Hommes; P Seeldrayers; P Soelberg-Sorensen
Journal:  Mult Scler       Date:  1995       Impact factor: 6.312

Review 2.  New insights into the immunogenetics of multiple sclerosis.

Authors:  J R Oksenberg; S L Hauser
Journal:  Curr Opin Neurol       Date:  1997-06       Impact factor: 5.710

Review 3.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives.

Authors:  R Hohlfeld
Journal:  Brain       Date:  1997-05       Impact factor: 13.501

4.  Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

Authors:  D H Miller; P S Albert; F Barkhof; G Francis; J A Frank; S Hodgkinson; F D Lublin; D W Paty; S C Reingold; J Simon
Journal:  Ann Neurol       Date:  1996-01       Impact factor: 10.422

5.  Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.

Authors:  D Barnes; R A Hughes; R W Morris; O Wade-Jones; P Brown; T Britton; D A Francis; G D Perkin; P Rudge; M Swash; H Katifi; S Farmer; J Frankel
Journal:  Lancet       Date:  1997-03-29       Impact factor: 79.321

6.  Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Authors:  K P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; R P Lisak; L W Myers; H S Panitch; J W Rose; R B Schiffer
Journal:  Neurology       Date:  1995-07       Impact factor: 9.910

7.  Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

Authors:  D E Goodkin; R A Rudick; S VanderBrug Medendorp; M M Daughtry; K M Schwetz; J Fischer; C Van Dyke
Journal:  Ann Neurol       Date:  1995-01       Impact factor: 10.422

Review 8.  The natural history of multiple sclerosis.

Authors:  B G Weinshenker
Journal:  Neurol Clin       Date:  1995-02       Impact factor: 3.806

9.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

Review 10.  Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis.

Authors:  C F Lucchinetti; W Brück; M Rodriguez; H Lassmann
Journal:  Brain Pathol       Date:  1996-07       Impact factor: 6.508
View more
  12 in total

1.  Drug treatment of multiple sclerosis. Clinical review was unsystematic.

Authors:  R Milne; A Clegg; J Bryant
Journal:  BMJ       Date:  2001-02-03

Review 2.  Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.

Authors:  David Murdoch; Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Authors:  Dene Simpson; Stuart Noble; Caroline Perry
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Nitric oxide and peroxynitrite in health and disease.

Authors:  Pál Pacher; Joseph S Beckman; Lucas Liaudet
Journal:  Physiol Rev       Date:  2007-01       Impact factor: 37.312

5.  Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL-6 production and Th17 differentiation.

Authors:  Wei Wei; Changsheng Du; Jie Lv; Guixian Zhao; Zhenxin Li; Zhiying Wu; György Haskó; Xin Xie
Journal:  J Immunol       Date:  2012-12-05       Impact factor: 5.422

Review 6.  Cannabinoids in multiple sclerosis: do they have a therapeutic role?

Authors:  Joep Killestein; Bernard M J Uitdehaag; Chris H Polman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Oxidative Stress and Lymphocyte Alterations in Chronic Relapsing Experimental Allergic Encephalomyelitis in the Rat Hippocampus and Protective Effects of an Ethanolamine Phosphate Salt.

Authors:  Aranzazu Perianes-Cachero; María V T Lobo; Alberto M Hernández-Pinto; Rebeca Busto; Miguel Angel Lasunción-Ripa; Eduardo Arilla-Ferreiro; Lilian Puebla-Jiménez
Journal:  Mol Neurobiol       Date:  2019-09-10       Impact factor: 5.590

8.  Disease modifying agents for multiple sclerosis.

Authors:  Olga Hilas; Priti N Patel; Sum Lam
Journal:  Open Neurol J       Date:  2010-05-26

9.  FTY720 in multiple sclerosis: the emerging evidence of its therapeutic value.

Authors:  Andrew Thomson
Journal:  Core Evid       Date:  2006-03-31

10.  Effects of adjunct low-dose vitamin d on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial.

Authors:  Vahid Shaygannejad; Mohsen Janghorbani; Fereshteh Ashtari; Hamed Dehghan
Journal:  Mult Scler Int       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.